EA5163: INSIGNA:

A Randomized Phase III Study of First-line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post-progression in Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Immuno-biomarker SIGNature-driven Analysis
Contact phone
Clinical Trials Office – 517.364.9400
Principal investigator
Gordan Srkalovic
Trial Category
Cancer
Trial SubCategory
Lung